{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:01:14Z","timestamp":1792522874190,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Child Adolesc Psychiatry"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1007\/s00787-012-0270-0","type":"journal-article","created":{"date-parts":[[2012,3,24]],"date-time":"2012-03-24T07:51:02Z","timestamp":1332575462000},"page":"361-368","source":"Crossref","is-referenced-by-count":46,"title":["Efficacy and safety of aripiprazole in child and adolescent patients"],"prefix":"10.1007","volume":"21","author":[{"given":"Eiji","family":"Kirino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,3,25]]},"reference":[{"issue":"3","key":"270_CR1","first-page":"464","volume":"10","author":"T Kikuchi","year":"2007","unstructured":"Kikuchi T (2007) The research and development of aripiprazole and its mechanism of action. Jpn J Clin Psychopharmacol 10(3):464\u2013468","journal-title":"Jpn J Clin Psychopharmacol"},{"issue":"12","key":"270_CR2","doi-asserted-by":"crossref","first-page":"923","DOI":"10.4088\/JCP.v62n1201","volume":"62","author":"SM Stahl","year":"2001","unstructured":"Stahl SM (2001) Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. J Clin Psychiatry 62(12):923\u2013924","journal-title":"J Clin Psychiatry"},{"issue":"1\u20133","key":"270_CR3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejphar.2005.02.051","volume":"515","author":"Y Tadori","year":"2005","unstructured":"Tadori Y, Miwa T, Tottori K, Burris KD, Stark A, Mori T et al (2005) Aripiprazole\u2019s low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. Eur J Pharmacol 515(1\u20133):10\u201319","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"270_CR4","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","volume":"60","author":"SG Potkin","year":"2003","unstructured":"Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E et al (2003) Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60(7):681\u2013690","journal-title":"Arch Gen Psychiatry"},{"key":"270_CR5","doi-asserted-by":"crossref","unstructured":"Lahti AC, Weiler MA, Corey PK, Lahti RA, Carlsson A, Tamminga CA (1998) Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia. Biol Psychiatry (Clinical Trial Controlled Clinical Trial Research Support, U.S. Gov\u2019t, P.H.S.) 43(1):2\u201311","DOI":"10.1016\/S0006-3223(97)00030-9"},{"key":"270_CR6","doi-asserted-by":"crossref","unstructured":"Tamminga CA, Carlsson A (2002 ) Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr Drug Targets CNS Neurol Disord 1(2):141\u2013147 (Review)","DOI":"10.2174\/1568007024606195"},{"key":"270_CR7","doi-asserted-by":"crossref","unstructured":"Tamminga CA (2002) Partial dopamine agonists in the treatment of psychosis. J Neural Transm 109(3):411\u2013420 (Review)","DOI":"10.1007\/s007020200033"},{"key":"270_CR8","doi-asserted-by":"crossref","unstructured":"Olbrich R, Schanz H (1991) An evaluation of the partial dopamine agonist terguride regarding positive symptoms reduction in schizophrenics. J Neural Transm Gen Sect. (Clinical Trial) 84(3):233\u2013236","DOI":"10.1007\/BF01244973"},{"issue":"6","key":"270_CR9","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1055\/s-2007-1017021","volume":"21","author":"R Olbrich","year":"1988","unstructured":"Olbrich R, Schanz H (1988) The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenics. Pharmacopsychiatry 21(6):389\u2013390","journal-title":"Pharmacopsychiatry"},{"issue":"8","key":"270_CR10","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","volume":"28","author":"DA Shapiro","year":"2003","unstructured":"Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR et al (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28(8):1400\u20131411","journal-title":"Neuropsychopharmacology"},{"issue":"25","key":"270_CR11","doi-asserted-by":"crossref","first-page":"15049","DOI":"10.1073\/pnas.95.25.15049","volume":"95","author":"LK Heisler","year":"1998","unstructured":"Heisler LK, Chu HM, Brennan TJ, Danao JA, Bajwa P, Parsons LH et al (1998) Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice. Proc Natl Acad Sci USA 95(25):15049\u201315054","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"270_CR12","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.pnpbp.2003.09.010","volume":"27","author":"HY Meltzer","year":"2003","unstructured":"Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003) Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27(7):1159\u20131172","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"5","key":"270_CR13","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2165\/00023210-200923050-00002","volume":"23","author":"C DeBattista","year":"2009","unstructured":"DeBattista C, Hawkins J (2009) Utility of atypical antipsychotics in the treatment of resistant unipolar depression. CNS Drugs 23(5):369\u2013377","journal-title":"CNS Drugs"},{"key":"270_CR14","doi-asserted-by":"crossref","unstructured":"Fernandez HH, Trieschmann ME, Friedman JH (2004) Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol 27(1):4\u20135","DOI":"10.1097\/00002826-200401000-00003"},{"issue":"11","key":"270_CR15","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/nn1146","volume":"6","author":"DJ Quervain de","year":"2003","unstructured":"de Quervain DJ, Henke K, Aerni A, Coluccia D, Wollmer MA, Hock C et al (2003) A functional genetic variation of the 5-HT2a receptor affects human memory. Nat Neurosci 6(11):1141\u20131142","journal-title":"Nat Neurosci"},{"issue":"Suppl 1","key":"270_CR16","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1055\/s-2006-931485","volume":"39","author":"G Grunder","year":"2006","unstructured":"Grunder G, Kungel M, Ebrecht M, Gorocs T, Modell S (2006) Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia. Pharmacopsychiatry 39(Suppl 1):S21\u2013S25","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"270_CR17","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/026988110401800308","volume":"18","author":"T Hirose","year":"2004","unstructured":"Hirose T, Uwahodo Y, Yamada S, Miwa T, Kikuchi T, Kitagawa H et al (2004) Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol 18(3):375\u2013383","journal-title":"J Psychopharmacol"},{"issue":"10","key":"270_CR18","doi-asserted-by":"crossref","first-page":"856","DOI":"10.4088\/JCP.v63n1002","volume":"63","author":"DA Wirshing","year":"2002","unstructured":"Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC (2002) The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 63(10):856\u2013865","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"270_CR19","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s002130050407","volume":"133","author":"PA Sargent","year":"1997","unstructured":"Sargent PA, Sharpley AL, Williams C, Goodall EM, Cowen PJ (1997) 5-HT2C receptor activation decreases appetite and body weight in obese subjects. Psychopharmacology 133(3):309\u2013312","journal-title":"Psychopharmacology"},{"issue":"1","key":"270_CR20","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.mp.4002066","volume":"13","author":"HA Nasrallah","year":"2008","unstructured":"Nasrallah HA (2008) Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 13(1):27\u201335","journal-title":"Mol Psychiatry"},{"key":"270_CR21","unstructured":"Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, et al (2003) H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology (Comparative Study Research Support, Non-U.S. Gov\u2019t Research Support, U.S. Gov\u2019t, P.H.S.) 28(3):519\u2013526"},{"issue":"12","key":"270_CR22","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1517\/14656566.3.12.1773","volume":"3","author":"PJ Goodnick","year":"2002","unstructured":"Goodnick PJ, Jerry JM (2002) Aripiprazole: profile on efficacy and safety. Expert Opin Pharmacother 3(12):1773\u20131781","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl 19","key":"270_CR23","first-page":"6","volume":"64","author":"SM Stahl","year":"2003","unstructured":"Stahl SM, Shayegan DK (2003) The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry 64(Suppl 19):6\u201312","journal-title":"J Clin Psychiatry"},{"key":"270_CR24","doi-asserted-by":"crossref","unstructured":"Bolden C, Cusack B, Richelson E (1992) Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther (Research Support, Non-U.S. Gov\u2019t Research Support, U.S. Gov\u2019t, P.H.S.) 260(2):576\u2013580","DOI":"10.1016\/S0022-3565(25)11335-9"},{"issue":"10 Suppl 11","key":"270_CR25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1017\/S1092852900025086","volume":"9","author":"DK Shayegan","year":"2004","unstructured":"Shayegan DK, Stahl SM (2004) Atypical antipsychotics: matching receptor profile to individual patient\u2019s clinical profile. CNS Spectr 9(10 Suppl 11):6\u201314","journal-title":"CNS Spectr"},{"key":"270_CR26","doi-asserted-by":"crossref","unstructured":"Davies MA, Sheffler DJ, Roth BL (2004) Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev 10(4):317\u2013336","DOI":"10.1111\/j.1527-3458.2004.tb00030.x"},{"key":"270_CR27","volume-title":"Practice guideline for the treatment of patients with schizophrenia","author":"American Psychiatric Association","year":"2004","unstructured":"American Psychiatric Association (2004) Practice guideline for the treatment of patients with schizophrenia, 2nd edn. American Psychiatric Association, Arlington (VA)","edition":"2"},{"issue":"6","key":"270_CR28","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00148581-200709060-00009","volume":"9","author":"M Sanford","year":"2007","unstructured":"Sanford M, Keating GM (2007) Aripiprazole: in adolescents with schizophrenia. Paediatr Drugs 9(6):419\u2013423","journal-title":"Paediatr Drugs"},{"issue":"9","key":"270_CR29","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1017\/S1092852900021519","volume":"12","author":"J Biederman","year":"2007","unstructured":"Biederman J, Mick E, Spencer T, Doyle R, Joshi G, Hammerness P et al (2007) An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder. CNS Spectr 12(9):683\u2013689","journal-title":"CNS Spectr"},{"issue":"10","key":"270_CR30","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.4088\/JCP.09m05164yel","volume":"70","author":"RL Findling","year":"2009","unstructured":"Findling RL, Nyilas M, Forbes RA, McQuade RD, Jin N, Iwamoto T et al (2009) Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 70(10):1441\u20131451","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"270_CR31","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1542\/peds.2008-3782","volume":"124","author":"R Owen","year":"2009","unstructured":"Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, McQuade RD et al (2009) Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 124(6):1533\u20131540","journal-title":"Pediatrics"},{"issue":"1","key":"270_CR32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1089\/cap.2008.0163","volume":"20","author":"AS Robb","year":"2010","unstructured":"Robb AS, Carson WH, Nyilas M, Ali M, Forbes RA, Iwamoto T et al (2010) Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: post hoc analysis of randomized clinical trial data. J Child Adolesc Psychopharmacol 20(1):33\u201338","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"270_CR33","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1185\/030079906X158075","volume":"23","author":"RR Aparasu","year":"2007","unstructured":"Aparasu RR, Bhatara V (2007) Patterns and determinants of antipsychotic prescribing in children and adolescents, 2003\u20132004. Curr Med Res Opin 23(1):49\u201356","journal-title":"Curr Med Res Opin"},{"issue":"11","key":"270_CR34","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1176\/appi.ajp.2008.07061035","volume":"165","author":"RL Findling","year":"2008","unstructured":"Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S et al (2008) A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 165(11):1432\u20131441","journal-title":"Am J Psychiatry"},{"issue":"3","key":"270_CR35","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3371\/CSRP.4.3.5","volume":"4","author":"E Kirino","year":"2010","unstructured":"Kirino E (2010) Prolonged catatonic stupor successfully treated with aripiprazole in an adolescent male with schizophrenia: a case report. Clin Schizophr Relat Psychoses 4(3):185\u2013188","journal-title":"Clin Schizophr Relat Psychoses"},{"issue":"5","key":"270_CR36","doi-asserted-by":"crossref","first-page":"756","DOI":"10.4088\/JCP.08m04726","volume":"70","author":"S Tramontina","year":"2009","unstructured":"Tramontina S, Zeni CP, Ketzer CR, Pheula GF, Narvaez J, Rohde LA (2009) Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit\/hyperactivity disorder: a pilot randomized clinical trial. J Clin Psychiatry 70(5):756\u2013764","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"270_CR37","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/CHI.0b013e3181b76658","volume":"48","author":"RN Marcus","year":"2009","unstructured":"Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH et al (2009) A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 48(11):1110\u20131119","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"270_CR38","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/cap.2008.093","volume":"19","author":"KA Stigler","year":"2009","unstructured":"Stigler KA, Diener JT, Kohn AE, Li L, Erickson CA, Posey DJ et al (2009) Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger\u2019s disorder: a 14-week, prospective, open-label study. J Child Adolesc Psychopharmacol 19(3):265\u2013274","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"6","key":"270_CR39","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2165\/00023210-200923060-00005","volume":"23","author":"G Masi","year":"2009","unstructured":"Masi G, Cosenza A, Millepiedi S, Muratori F, Pari C, Salvadori F (2009) Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: a retrospective study. CNS Drugs 23(6):511\u2013521","journal-title":"CNS Drugs"},{"issue":"4","key":"270_CR40","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1089\/cap.2007.0124","volume":"18","author":"RL Findling","year":"2008","unstructured":"Findling RL, Short EJ, Leskovec T, Townsend LD, Demeter CA, McNamara NK et al (2008) Aripiprazole in children with attention-deficit\/hyperactivity disorder. J Child Adolesc Psychopharmacol 18(4):347\u2013354","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"7","key":"270_CR41","first-page":"1088","volume":"68","author":"HK Yoo","year":"2007","unstructured":"Yoo HK, Choi SH, Park S, Wang HR, Hong JP, Kim CY (2007) An open-label study of the efficacy and tolerability of aripiprazole for children and adolescents with tic disorders. J Clin Psychiatry 68(7):1088\u20131093","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"270_CR42","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1089\/cap.2007.0064","volume":"18","author":"WS Seo","year":"2008","unstructured":"Seo WS, Sung HM, Sea HS, Bai DS (2008) Aripiprazole treatment of children and adolescents with Tourette disorder or chronic tic disorder. J Child Adolesc Psychopharmacol 18(2):197\u2013205","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"9","key":"270_CR43","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1097\/01.chi.0000132834.43268.10","volume":"43","author":"WC Myers","year":"2004","unstructured":"Myers WC, Ruiz R (2004) Aripiprazole and psychotherapy for delusional disorder, erotomanic type. J Am Acad Child Adolesc Psychiatry 43(9):1069\u20131070","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"270_CR44","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/da.20303","volume":"25","author":"EA Storch","year":"2008","unstructured":"Storch EA, Lehmkuhl H, Geffken GR, Touchton A, Murphy TK (2008) Aripiprazole augmentation of incomplete treatment response in an adolescent male with obsessive-compulsive disorder. Depress Anxiety 25(2):172\u2013174","journal-title":"Depress Anxiety"},{"issue":"16","key":"270_CR45","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","volume":"302","author":"CU Correll","year":"2009","unstructured":"Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK (2009) Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302(16):1765\u20131773","journal-title":"JAMA"},{"key":"270_CR46","doi-asserted-by":"crossref","unstructured":"Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, et al (2009) The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 70(Suppl 4):1\u201346 (quiz 7\u20138)","DOI":"10.4088\/JCP.7090su1cj"}],"container-title":["European Child & Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s00787-012-0270-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T19:11:08Z","timestamp":1742757068000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00787-012-0270-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,25]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["270"],"URL":"https:\/\/doi.org\/10.1007\/s00787-012-0270-0","relation":{},"ISSN":["1018-8827","1435-165X"],"issn-type":[{"value":"1018-8827","type":"print"},{"value":"1435-165X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,25]]}}}